Rigel Pharmaceuticals Reports Record 2025 Financial Results and Bullish Outlook for 2026

Key Highlights for Investors

• Record 2025 Performance: Rigel Pharmaceuticals, Inc. reported record-breaking financial results for the fourth quarter and full year 2025, driven by robust growth in product sales across its hematology and oncology portfolio.
• Substantial Revenue and Income Growth: Full-year 2025 total revenues reached \$294.3 million, up 64% from 2024, with net product sales of \$232.0 million (up 60%). The company posted a net income of \$367.0 million, a massive increase compared to \$17.5 million in 2024, reflecting a one-time non-cash deferred income tax benefit of \$245.9 million.
• Strong Fourth Quarter: Q4 2025 total revenues were \$69.8 million (up 21% year-over-year), with net product sales of \$65.4 million (up 41%). Q4 net income was \$268.1 million, compared to \$14.3 million in Q4 2024.
• Significant Sales Growth Across Portfolio:
  • TAVALISSE®: Net product sales of \$158.8 million for 2025, up 52% year-over-year.
  • GAVRETO®: Net product sales of \$42.1 million, up 146% since Rigel began commercialization in mid-2024.
  • REZLIDHIA®: Net product sales of \$31.0 million, up 35%.
• Cash Position: Ended 2025 with \$155.0 million in cash, cash equivalents, and short-term investments, more than doubling from \$77.3 million at the end of 2024.
• 2026 Financial Guidance: Rigel anticipates 2026 total revenues of \$275–\$290 million, with net product sales of \$255–\$265 million, and expects to report positive net income while funding ongoing and new clinical development programs.

Business and Clinical Developments

• Progress in R289 Clinical Program: Enrollment is ongoing in the dose expansion phase of a Phase 1b study of R289 in relapsed/refractory lower-risk myelodysplastic syndrome (MDS). Rigel aims to complete enrollment and select the recommended Phase 2 dose in H2 2026, with preliminary data expected by year-end 2026.
• Promising R289 Data at ASH 2025: Updated data showed R289 was generally well tolerated in a heavily pretreated MDS population. Notably, 33% of transfusion-dependent patients (6/18) receiving 500 mg QD or higher achieved transfusion independence (≥8 weeks) — a potentially important efficacy signal.
• Olutasidenib Pipeline Expansion: Four posters on olutasidenib (REZLIDHIA) were presented at ASH 2025, supporting its use in relapsed/refractory mutated IDH1 AML. The CONNECT Phase 2 TarG-D study was initiated, evaluating olutasidenib plus temozolomide in newly diagnosed high-grade glioma with IDH1 mutation.
• Pralsetinib (GAVRETO) Developments:
  • Presented efficacy and safety data at the 2025 NACLC and 2026 ASCO-GI, demonstrating robust and durable activity in RET fusion-positive solid tumors, including GI cancers, with overall response rates of 67% in the TAPISTRY study.
  • FDA updated GAVRETO’s U.S. Prescribing Information to include a boxed warning for serious infections in December 2025. Rigel has already communicated this to healthcare providers.
  • FDA confirmed fulfillment of certain postmarketing commitments and granted full approval to GAVRETO for metastatic RET fusion-positive NSCLC.
• Significant Publication: Final five-year results from the pivotal Phase 2 trial of olutasidenib in R/R mIDH1 AML published in the Journal of Hematology & Oncology, demonstrating durable responses and a manageable safety profile, including in patients previously treated with venetoclax-based regimens.
• Corporate Update: Appointment of Michael P. Miller as an independent director and Compensation Committee member, effective February 1, 2026.

Shareholder-Relevant, Potentially Price-Sensitive Information

• Record Revenue and Profitability: The magnitude of revenue and net income growth, driven by both commercial execution and a large, non-cash tax benefit, is a significant positive surprise and could be price moving.
• Strong 2026 Guidance: Despite a projected decrease in total revenue (due to lower contract revenue), Rigel expects higher net product sales and continued profitability, supporting confidence in the core business and pipeline sustainability.
• Pipeline Advancements: The advancement of R289 into late-stage development, with preliminary efficacy signals and a path to Phase 2, offers clear upside if confirmed in future data. Expansion into new indications (e.g., high-grade glioma) for olutasidenib and robust pralsetinib data across multiple tumor types also provide future catalysts.
• Regulatory Update: The addition of a boxed warning for GAVRETO is a risk factor investors must monitor, though mitigated by prior communications and full FDA approval for NSCLC, which de-risks the asset.
• Financial Strength: The strengthened cash position more than doubles the company’s liquidity, supporting pipeline investment without near-term financing risk.

Detailed Financial Results

• 2025 Full Year Results:
  • Total revenues: \$294.3 million (vs. \$179.3 million in 2024)
  • Net product sales: \$232.0 million (vs. \$144.9 million in 2024)
  • Contract revenues: \$62.3 million (vs. \$34.4 million in 2024)
  • Net income: \$367.0 million (vs. \$17.5 million in 2024), or \$20.40 basic and \$19.48 diluted per share
  • Total costs and expenses: \$168.8 million (vs. \$155.1 million in 2024)
  • Cash, cash equivalents, and short-term investments at year-end: \$155.0 million (vs. \$77.3 million in 2024)
• Q4 2025 Results:
  • Total revenues: \$69.8 million (vs. \$57.6 million in Q4 2024)
  • Net product sales: \$65.4 million (vs. \$46.5 million in Q4 2024)
  • Net income: \$268.1 million (vs. \$14.3 million in Q4 2024), or \$14.72 basic and \$13.54 diluted per share
• 2026 Outlook:
  • Total revenues: \$275–\$290 million
  • Net product sales: \$255–\$265 million
  • Contract revenues: \$20–\$25 million
  • Continued positive net income, while investing in clinical programs

Upcoming Catalysts

• Completion of R289 dose expansion enrollment and Phase 2 dose selection in H2 2026
• Preliminary data from R289 Phase 1b dose expansion by year-end 2026
• Potential future label expansion for olutasidenib and pralsetinib, based on ongoing studies
• Further business development and partnership milestones possible

Risks and Considerations

• FDA-mandated boxed warning for GAVRETO may affect prescriber confidence and market uptake.
• Ongoing clinical development carries risks of delays, negative data, or regulatory setbacks.
• Revenue growth in 2025 was partly driven by one-time contract and tax items; investors should closely monitor sustainability of core product growth.
• Market competition, reimbursement dynamics, and evolving treatment paradigms in hematology and oncology remain ongoing challenges.

Conclusion

Rigel Pharmaceuticals delivered a standout year in 2025, with record revenues, dramatic profitability, and operational progress across its marketed and pipeline assets. The company’s guidance for 2026 projects continued growth in product sales and ongoing profitability, while sustaining investment in late-stage clinical development. Multiple clinical and regulatory catalysts are expected in 2026, with the potential to drive further value for shareholders. However, investors should remain attentive to regulatory, clinical, and commercial risks, especially relating to GAVRETO’s boxed warning and the sustainability of growth drivers.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial professionals before making investment decisions. The information presented is based on publicly available company disclosures as of the date of this article and may be subject to change.

View RIGEL PHARMACEUTICALS INC Historical chart here